Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-06-29
Item 5.07
This is a clear disclosure of shareholder voting results from AleAnna's June 26, 2026 Annual Meeting of Stockholders under Item 5.07. The filing reports the voting outcomes for two proposals: election of Class II directors (Curtis Hébert Jr. and William K. Dirks) and ratification of Deloitte & Touche LLP as independent auditor, with detailed vote tallies showing both proposals were approved. This is a routine but material governance disclosure required by Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-29
The filing discloses results of the 2026 annual meeting of stockholders held on June 29, 2026, with detailed voting tallies for five proposals including director elections, auditor ratification, equity plan amendment, warrant issuance authorization, and reverse stock split approval. Item 5.07 explicitly presents voting results with vote counts for each proposal, which is the defining characteristic of shareholder_vote_results. The equity plan amendment and warrant issuance approvals are material governance and capital structure decisions requiring shareholder authorization.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-06-29
Item 2.03
The Company drew $5,000 thousand under an unsecured promissory note dated January 30, 2024 with Constellation Sponsor LP, creating a direct financial obligation. While this is technically a draw on an existing note rather than a new issuance, it represents the creation of a new financial obligation at the time of drawdown. The funds were deposited into the trust account to extend the business combination deadline, which is material to shareholders evaluating the Company's timeline and sponsor support.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-29
Item 5.07
This Item 5.07 filing discloses the results of an extraordinary general meeting of CEPT shareholders held on June 29, 2026, where shareholders voted on four major proposals including approval of a Business Combination Agreement with Securitize, Inc., the CEPT Merger, organizational documents for the post-merger entity (PubCo), and Nasdaq Rule 5635 compliance. All proposals received requisite shareholder approval, with Proposal 1 (Business Combination) receiving 12,432,037 votes for, 2,151,147 against, and 197,157 abstentions. The filing explicitly states that "In light of receipt of the requisite approvals by CEPT Shareholders described above, CEPT expects the Business Combination to be completed promptly," confirming this is a material shareholder vote result that clears the path for a transformative M&A transaction.
View raw filing on EDGAR →
6-K
Governance Other
confidence 70%
filed 2026-06-29
EX-99.1
Jin Medical International held shareholder meetings (Class A, Class B, and Extraordinary General Meeting) on July 9, 2026, to vote on multiple material proposals including a VIE acquisition, voting-rights changes (Class B voting rights increase from 30 to 800 votes per share), a related-party share repurchase of 3.77M Class A shares from CEO Wang Erqi's entity (Jolly Harmony) at 90-day VWAP, and issuance of 3.77M Class B shares to the same entity, as well as authorized capital increase.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-06-29
Item 5.03
GD Culture Group effected a 1-for-250 reverse stock split of its authorized and issued shares, approved by the Board on June 16, 2026 and effective June 29, 2026, consolidating approximately 1.04 billion shares into approximately 4.16 million shares. The reverse split was previously approved by stockholders on December 31, 2025, and a Certificate of Change was filed with Nevada's Secretary of State on June 18, 2026. This capital structure adjustment affects all shareholders uniformly and impacts the company's trading characteristics on Nasdaq.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-29
The 6-K discloses results of an Extraordinary General Meeting of Shareholders held on June 29, 2026, where shareholders approved four material resolutions: (1) acquisition of 80–100% of Psyga Bio Ltd. via private placement of shares and warrants; (2) private placement of up to $1.5M from specified investors; (3) increase of authorized share capital by 2.9B shares; and (4) appointment of auditors. This is a classic shareholder vote results disclosure under Item 5.07 equivalent, and the underlying transactions (M&A, dilutive issuance, auditor appointment) are material to investors.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-29
Item 5.02
Albert Rabil III resigned from the Board of Directors of Kayne DL 2021, Inc., effective immediately on June 29, 2026. The filing explicitly discloses his departure as a Class III director with a remaining term through 2029. While the company confirms the resignation was not due to disagreement, the departure of a board member is a material governance event affecting the composition and independence structure of the board.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-29
Item 5.02
Albert Rabil III resigned from the Board of Directors of Kayne Anderson BDC, Inc., effective immediately on June 29, 2026. As a Class III director with a remaining term through 2029, his departure is a material change to the board composition. The filing explicitly confirms the resignation was not due to disagreement, and notes the board composition shifted from seven to six directors with four remaining independent directors.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-29
EX-99.1
WISeKey has signed a merger agreement with its wholly owned British Virgin Islands subsidiary to effect a redomiciliation from Switzerland to the BVI. The merger involves a change of control structure where WISeKey merges into WISeKey BVI, with WISeKey BVI surviving as the publicly traded parent company. This is a material acquisition/change of control transaction requiring shareholder approval at an extraordinary general meeting, SEC registration, and Nasdaq/SIX listing authorizations.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-29
Item 5.02
Leonardo Viana Nicacio, M.D., the Company's Chief Medical Officer, resigned effective June 26, 2026 to explore other opportunities. This is a clear departure of a named executive officer. While the filing notes that his duties will be assumed by existing personnel (Carla Beckham and oversight by Jacqueline Zummo), the principal disclosed action is the resignation of a C-suite executive, making this an exec_departure event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-29
Item 5.07
This is a clear disclosure of shareholder vote results from a reconvened annual meeting held on June 23, 2026. The filing reports the outcomes of two proposals: (1) election of Ronald J. Kramer and Leslie D. Michelson as Class III directors, with specific vote tallies (For/Against/Abstain), and (2) stockholder approval to authorize sales of Common Stock below net asset value, with detailed voting results. This directly matches the shareholder_vote_results event type and Item 5.07 disclosure requirement.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-29
Item 5.07
Western Uranium & Vanadium held its Annual General and Special Meeting of Shareholders on June 26, 2026, with shareholder approval of director re-elections (George Glasier, Bryan Murphy, Andrew Wilder, Michael Skutezky), reappointment of MNP LLP as auditor, and reapproval of the 2023 Incentive Stock Option Plan and 2023 Shareholder Rights Plan.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-29
Item 5.02
The filing discloses the appointment of John P. Sharp as Interim Chief Financial Officer on June 25, 2026, replacing Quang X. Pham. While the section also includes a director resignation (Steven Zelenkofske) and board realignment, the principal disclosed action centers on the CFO appointment, which is material to investors as it affects the company's financial leadership. The detailed biography and compensation terms ($455/hour for up to 24 hours/week under a Master Services Agreement) underscore the significance of this executive appointment.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-29
Item 7.01
The company announced its inclusion in the Russell Microcap® Index effective June 29, 2026, which enhances market visibility and is material to institutional investors due to its impact on investment flows and index-tracking fund participation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-29
The filing discloses results of a special meeting of stockholders held on June 24, 2026, where three proposals were voted on and approved: (i) approval of issuance of shares upon exercise of restricted common stock purchase warrants from the February 2026 Private Placement; (ii) approval of issuance of shares upon conversion of Series B Convertible Preferred Stock; and (iii) authorization for the Board to effect a reverse stock split at a ratio between one-for-two and one-for-two hundred fifty. This is a classic Item 5.07 shareholder vote results disclosure with material implications for capital structure and dilution.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-29
Item 8.01
This disclosure announces the completion of a SPAC's IPO, full exercise of the underwriters' over-allotment option (bringing total units to 23 million and gross proceeds to $230 million), and the commencement of separate trading of Class A Ordinary Shares and Warrants on the NYSE. While the IPO itself is a capital-raising event material to investors, it does not fit neatly into the standard taxonomy categories (not earnings_release, debt_issuance, dilutive_issuance, or dividend_distribution). The event is clearly financial and material, but the taxonomy lacks a dedicated SPAC IPO or capital-raising category, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-29
Item 5.07
Quantum Computing Inc. held its Annual Meeting on June 24, 2026, with shareholders voting on five proposals: election of six directors, advisory vote on named executive officer compensation, ratification of independent auditor BPM LLP, approval of a Certificate of Incorporation amendment increasing authorized shares from 260 million to 460 million, and approval of an amendment to the 2022 Equity and Incentive Plan increasing authorized shares from 20 million to 30 million and modifying the evergreen provision.
View raw filing on EDGAR →
8-K
Governance Other
confidence 72%
filed 2026-06-29
Item 3.03
The Company disclosed a material modification to the rights of security holders, which incorporates amendments to the Certificate of Incorporation and related governance documents affecting voting power, dividend rights, or other fundamental security characteristics.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-29
EX-99.1
The press release announces the closing of a registered direct offering of 3,149,832 ordinary shares at $1.97 per share, generating approximately $6.2 million in gross proceeds. This is a registered equity issuance that dilutes existing shareholders. The offering was conducted pursuant to a shelf registration statement on Form F-3, making it a registered (not unregistered) offering, but it remains a material capital-raising event that increases share count and dilutes ownership. The company explicitly states use of proceeds for general corporate purposes, strategic expansion, and acquisition-related costs.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Troy W. Ingianni was appointed as Chief Financial Officer, Secretary and Treasurer of TransAct Technologies Inc., effective July 1, 2026, following the retirement of Steven A. DeMartino. Ingianni brings 25+ years of financial leadership experience and was appointed by the Board on June 26, 2026.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-29
EX-99.1
This news release announces exploration drilling results at Collective Mining's Apollo system in Colombia, disclosing the discovery of a new high-grade tungsten-enriched subzone 300 meters below surface with assay results of 27.35m @ 37.55 g/t AuEq (1.68% WO3, 11.62 g/t Au, 54 g/t Ag, 0.43% Cu). The disclosure is a material operational/exploration milestone for an early-stage mining exploration company, demonstrating significant expansion of the Apollo system's scale and depth potential with multiple high-grade intercepts. While not a discrete M&A, financing, or governance event, this exploration success is material to investors' assessment of the company's asset value and development trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-29
EX-99.1
IsoEnergy discloses a wildfire near its Larocque East project in Saskatchewan that has forced temporary evacuation of field personnel and suspension of exploration activities. While the fire does not currently pose a direct threat to the project site, the Saskatchewan Public Safety Agency has deemed conditions too dangerous for work to proceed. The company expects personnel to remain away for up to one week, though it notes this should not materially impact completion of its 8,000-metre drill program. This is an operational disruption event—a material business interruption caused by external natural phenomena—that does not fit the specific categories of workforce reduction, material litigation, or other named types, but clearly affects the company's near-term operational capacity and project timeline.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-06-29
EX-99.1
The disclosure announces a reset of the interest rate on $1 billion principal amount of Limited Recourse Capital Notes Series 2021-1 from 3.60% to 5.614% per annum for the five-year period commencing June 30, 2026. While this is technically a modification of existing debt rather than a new issuance, the material change in interest rate terms on a $1 billion subordinated debt instrument is a significant financial obligation event that would affect investor assessment of the company's cost of capital and financial obligations. The announcement is structured as a debt-related disclosure under the trust indenture framework.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
The filing discloses a related-party transaction in which AXIA Energia and three subsidiaries assigned rights to use Optical Ground Wire (OPGW) cables and associated transmission infrastructure to Eletronet (a wholly-owned subsidiary) for telecommunications services. The transaction is valued at BRL 125,099,251.20 with a 20-year term and complies with ANEEL Normative Resolution No. 1,044/2022. This is a material operational/strategic arrangement involving infrastructure sharing and asset monetization that would affect a reasonable investor's assessment of the company's capital deployment and subsidiary operations.
View raw filing on EDGAR →
6-K
Governance Other
confidence 65%
filed 2026-06-29
EDENOR disclosed an upgrade of its issuer credit rating by S&P National Ratings from "raA+" to "raAA-", with outlook change from positive to stable. While credit rating changes are material to investors assessing financial risk and cost of capital, they do not fit neatly into the standard 8-K taxonomy. The disclosure is governance-adjacent (relating to the company's financial standing and market perception) rather than a discrete operational, financial, or legal event. Classified as governance_other because the domain is clearly governance/market-related but no specific named type applies.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-29
The 6-K furnishes a consolidated synthetic remote voting map for an Extraordinary General Meeting held on June 30, 2026, disclosing voting results on six resolutions. The core resolutions (Items 1–5) concern approval of a merger of Esfera Fidelidade S.A. into Banco Santander (Brasil), including ratification of the appraiser (PricewaterhouseCoopers), approval of the appraisal report, and approval of the merger protocol and transaction itself. These are material M&A-related shareholder votes with overwhelming approval (59+ million votes for on common shares). The disclosure is a post-vote reporting of shareholder approval results, fitting the shareholder_vote_results category under Item 5.07 equivalent.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-06-29
Braskem discloses that Fitch Ratings and S&P Global Ratings have downgraded the Company's corporate credit rating to C and D respectively, in connection with a Precautionary Injunctive Relief proceeding. These are distressed-level credit ratings that signal severe financial stress and heightened delisting risk. While the filing does not explicitly mention delisting, the combination of emergency legal proceedings and catastrophic credit downgrades to near-default levels creates material delisting risk under NYSE continued listing standards.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-06-29
Item 7.01
Alliance announced a credit ratings upgrade from Moody's on its corporate family rating and senior secured debt facilities (B2 to B1), resulting in a 25 basis point reduction in borrowing costs on its term loan. While this is a positive financial development reflecting improved creditworthiness and enhanced financial flexibility, it does not fit neatly into the specific financial event categories (debt_issuance, covenant_breach, material_impairment, etc.). The upgrade is material to investors as it signals improved financial health and reduced future financing costs, but the event itself is a third-party credit rating action rather than a direct financial transaction or accounting event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-29
Item 1.01
Emergent BioSolutions announced a contract modification valued at $52.7 million from the U.S. Department of Health and Human Services for supply of ACAM2000® vaccine under an existing 10-year government contract, representing a material operational and revenue milestone.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-29
Item 5.07
This Item 5.07 filing discloses the results of Niagen Bioscience's 2026 Annual Meeting of Stockholders, including voting outcomes for three proposals: election of eight directors, ratification of Crowe LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (For, Against, Abstain, and Broker Non-Votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder vote results.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-29
Item 8.01
Neurogene disclosed positive clinical trial data from its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome, including 47 developmental milestones gained across 10 participants with durable effects through 30 months and no treatment-related serious adverse events.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
EX-99.1
This is a company announcement of positive Phase 3 clinical trial results for epcoritamab (EPCORE DLBCL-4), demonstrating statistically significant improvement in progression-free survival. While the announcement discloses clinical development progress rather than financial results, regulatory approval, or a discrete corporate event, the positive Phase 3 data for a key pipeline asset in a major indication (relapsed/refractory DLBCL) represents material operational/strategic progress that would affect a reasonable investor's assessment of the company's pipeline value and commercial prospects. This is classified as operational_other because it is clearly an operational/strategic milestone (clinical trial success) that does not fit the earnings_release category (which is for financial results) or other specific event types.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Dr. Joe Xiao was appointed to the Board of Directors on June 23, 2026, and simultaneously appointed to three key committees (Audit, Compensation, and Nominating and Corporate Governance). The disclosure centers on the appointment action itself, not on compensation arrangements or departures. Board appointments are material to investors as they affect governance and oversight.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-29
Item 7.01
Creative Realities announced commencement of a public underwritten offering of common stock and pre-funded warrants, with an underwriter option for an additional 12.5% of shares. Proceeds will be used for working capital, debt paydown, and potential acquisitions under an effective Form S-3 shelf registration.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-29
EX-99.1
Bullish announced receipt of regulatory approval from the Gibraltar Financial Services Commission (GFSC) to offer trading in tokenized securities, positioning the company among the first regulated venues to do so. This is a material operational and strategic milestone that advances Bullish's broader strategy to build end-to-end infrastructure for tokenized securities, particularly in conjunction with its pending acquisition of Equiniti. The approval enables a new business line and regulatory capability that would affect investor assessment of the company's growth prospects and competitive positioning.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-29
Item 5.07
NRC Health held its Annual Meeting of Stockholders on June 23, 2026, with shareholders voting on six proposals: election of seven directors, ratification of KPMG LLP as auditor, an advisory vote on named executive officer compensation, and three amendments to the certificate of incorporation. The detailed voting results for each proposal are disclosed.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-06-29
Item 5.03
Stockholders approved and the board adopted amendments to NRC Health's certificate of incorporation and bylaws that materially alter the Company's governance structure, including removal of supermajority voting requirements, elimination of restrictions on director removal without cause, and lowering the threshold for stockholder action by written consent from unanimous to a simple majority.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-29
Item 4.01
The Company dismissed BCRG as its independent registered public accounting firm and appointed Simon & Edward LLP as the new auditor, effective June 26, 2026, following S&E's acquisition of BCRG's attest business. This is a classic auditor change disclosed under Item 4.01, with no adverse opinions, disagreements, or reportable events noted, indicating a routine transition driven by the acquisition rather than accounting or audit concerns.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-29
Item 5.07
This Item 5.07 disclosure reports the results of the Company's Annual Meeting of Stockholders held on June 24, 2026, including voting outcomes on three proposals: election of five directors, advisory approval of named executive officer compensation, and ratification of PwC as independent auditor. The filing presents vote tallies (For, Against, Abstentions, Broker Non-Votes) for each proposal, confirming all three passed with substantial majorities. This is a textbook shareholder_vote_results disclosure.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-29
Item 5.03
Barrel Energy Inc. filed a Corrective Amendment to its Certificate of Designation for Series A Preferred Stock on June 22, 2026, clarifying a 1:1,000 conversion ratio for 5 million preferred shares, representing 5 billion shares of common stock upon conversion. This amendment materially modifies shareholder rights and represents significant potential dilution to existing shareholders' equity and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
Nexscient issued 816,000 restricted shares of common stock to two executive officers (President & CEO Fred Tannous and COO Tarek Shoufani) in settlement of $204,000 in accrued wages, relying on Section 4(a)(2) exemption from Securities Act registration. This is a classic unregistered equity issuance under Item 3.02, diluting existing shareholders. The transaction is material because it represents a significant equity grant to related parties and signals cash preservation concerns ahead of a planned uplisting.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-06-29
Item 7.01
The disclosure reports receipt of approximately $57 million in cash from Eli Lilly's acquisition of Ajax Therapeutics, a company co-founded by Schrödinger, plus eligibility for additional milestone-based payments. This is a financial event involving a material cash inflow and contingent consideration, but does not fit the specific M&A categories (which typically apply when the registrant itself is acquired or makes an acquisition) since Schrödinger is receiving proceeds from a third-party acquisition of an affiliate. The event is material to investors as it represents a significant capital receipt and future contingent cash flows.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-29
The filing discloses a registered direct offering of 11,038,767 shares of Class A common stock at $0.165 per share, generating approximately $1.8 million in gross proceeds. This is a material dilutive equity issuance under Item 1.01. While Item 5.02 also reports Alan Gaines' board resignation, the primary substantive event disclosed is the equity offering, which materially affects shareholder ownership and capital structure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
EX-99.1
VivoPower announces selection of a preferred long-term tenant for its Mo i Rana AI data center in Norway, with further arrangements under negotiation across the company's wider pipeline. This is a material operational and strategic business development—the selection of a major tenant for a core asset and potential expansion of the relationship across multiple jurisdictions—but does not fit a discrete event category (not M&A, not a financing event, not a contract disclosure with specific terms). The announcement is conditional on execution of legal documentation and defers material commercial terms to a future announcement, making it a strategic milestone rather than a completed transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 1.01
U.S. GoldMining entered into a securities purchase agreement to issue 522,876 shares of common stock at $7.65 per share in a registered direct offering, generating approximately $4.0 million in gross proceeds. This is a registered equity issuance that dilutes existing shareholders and represents a material capital-raising event for the company, with proceeds designated for working capital and general corporate purposes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-29
Item 3.02 discloses unregistered sales of common stock and warrant exercises during Q2 2026 under Section 4(a)(2) exemption, totaling approximately $7.36 million in gross proceeds. Item 7.01 provides detailed capital activity breakdown including multiple equity issuances at varying prices and warrant exercises. This represents a material dilutive equity issuance that would affect shareholder ownership and is a key indicator of capital-raising activity at a small-cap company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-29
The 8-K discloses financial results for fiscal year ended March 31, 2026, with net income of $1,305,722 ($0.64 per diluted share, down 24% YoY) and operating revenues of $6,561,324 (down 8% YoY). Item 2.02 explicitly states the registrant "issued a news release to announce its financial results," and the attached Exhibit 99.1 is a press release reporting annual earnings with detailed operational and reserve metrics. This is a standard earnings release disclosure.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-29
The filing discloses under Item 4.01 the dismissal of WithumSmith+Brown, PC as the independent registered public accounting firm effective June 26, 2026, and the concurrent engagement of Grant Thornton LLP as the new auditor. The filing explicitly states no disagreements or reportable events occurred, and the prior audit report contained no adverse opinions or qualifications, indicating a routine auditor transition rather than one driven by accounting disputes.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-29
Atlas Lithium disclosed receipt of an expansion permit from the permitting commission of Minas Gerais, Brazil on June 26, 2026, authorizing assembly and operation of its lithium processing plant and sale of lithium concentrate. This is a material operational and regulatory milestone that enables advancement of the Company's Neves Project as outlined in its Definitive Feasibility Study, but does not fit the specific categories of M&A activity, debt issuance, workforce reduction, or other named event types.
View raw filing on EDGAR →